New Data Support Hemlibra Efficacy Across Dosing Schedules in Hemophilia A with Factor VIII Inhibitors


Updated data from the HAVEN 2 study showed that the majority of children treated with emiciziumab-kxwh (Hemlibra, Genentech) experienced sustained bleed control.

Treatment with emiciziumab-kxwh (Hemlibra, Genentech) demonstrated sustained bleed control across 3 different dosing schedules in the majority of children with hemophilia A with factor VIII inhibitors, according to updated data from the phase 3 HAVEN 2 study.

Results from the study were presented at the 60th American Society of Hematology (ASH) Annual Meeting.

The HAVEN 2 study evaluated emiciziumab-kxwh prophylaxis in children younger than 12 years of age with hemophilia A with factor VIII inhibitors, including longer follow-up for once-weekly dosing and less frequent dosing schedules. The primary analysis included 85 children and the intra-patient comparison included 18 patients from the once-weekly cohort previously treated with bypassing agents (BPAs), either as prophylaxis or on-demand.

Emiciziumab-kxwh is designed to bring together factor IXa and factor X, proteins required to activate the natural coagulation cascade and restore the blood clotting process for patients with hemophilia A, according to the press release.

Based on the new data from a median of 11 additional months, 76.9% (95% CI: 64.8; 86.5) of children treated with emiciziumab-kxwh once weekly experienced 0 treated bleeds. Additionally, a prospective intra-patient comparison showed that once-weekly dosing demonstrated a 99% reduction in treated bleeds compared with prior treatment with BPAs as prophylaxis or on-demand. New data demonstrated clinically meaningful bleed control at dosing schedules of 2 weeks and 4 weeks, with 90% (95% CI: 55.5; 99.7) and 60% (95% CI: 26.2; 87.8) of children with factor VIII inhibitors experiencing 0 treated bleeds, respectively.

These data reinforce emiciziumab-kxwh’s ability to provide sustained and effective bleed control with the option for different treatment schedules, according to Genentech.

“The updated analysis from the HAVEN 2 study supports the potential of Hemlibra to control bleeds at less frequent subcutaneous dosing, providing parents and their children more flexibility to choose a treatment schedule that is right for them,” Sandra Horning, MD, chief medical officer and head of Global Product Development at Genentech, said in a statement.

In October 2018, the FDA also approved emiciziumab-kxwh for use in patients of all ages with hemophilia A without factor VIII inhibitors. It is currently the only approved treatment for those with and without factor VIII inhibitors that can be administered subcutaneously and at multiple dosing schedules, according to the release.


Genentech’s Hemlibra (emiciziumab-kxwh) Provided Sustained Bleed Control in the Largets Pivotal Study to Date of Children With Hemophilia Factor VIII Inhibitors [news release]. Genentech’s website. Accessed December 12, 2018.

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 -
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder -
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff -
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk -
Capsules medicine and white medicine bottles on table | Image Credit: Satawat -
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn -
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg -
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl -
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka -
Bottle and scattered pills on color background, top view | Image Credit: New Africa -
© 2024 MJH Life Sciences

All rights reserved.